CTLA4 and melanoma: Herein, the urothelial cancer database (IMvigor210) consisting of anti-PD-L1 therapy and the malignant melanoma database (GSE91016) administered with anti-PD-1 and-CTLA-4 therapy were used to investigate the association between risk score and immunotherapeutic benefits.